Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy

NCT03244657 is registered in ClinicalTrials.gov with Chengdu Kanghong Biotech Co., Ltd. as lead sponsor.

NCT NCT03244657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03244657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy
Lead sponsor
Chengdu Kanghong Biotech Co., Ltd.
Phase
Phase 4
Overall status
Unknown status
Start date
April 25, 2017
Completion date
February 28, 2020
Enrollment
200 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

polypoid choroidal vasculopathy (pcv)